Fuji Pharma (4554) FY2026 Q1 Earnings Report

Quick View

Executive Summary

FY2026 Q1 results: Revenue 159.0B yen (YoY +22.3%), Operating Income 27.9B yen (YoY +122.4%), Ordinary Income 26.5B yen (YoY +92.8%), Net Income 3.2B yen (YoY -67.2%). The quarter demonstrated robust top-line expansion and significant operating profit improvement, with operating margin reaching approximately 17.5% compared to 9.6% in the prior year period. However, extraordinary losses of 24.6B yen primarily from impairment of investment securities substantially reduced net income despite strong operational performance. Full-year forecast projects revenue of 592.5B yen (+14.7% YoY), operating income of 61.2B yen (+22.6% YoY), and net income of 22.4B yen.

Key Metrics

[Profitability] Operating margin 17.5% (improved from 9.6% YoY), gross profit margin 42.9%, net profit margin 2.0% (declined from 7.6% YoY due to extraordinary losses). ROE 0.7% based on quarterly net income, substantially below the historical trend. EBIT margin of 17.5% indicates strong operational efficiency, but the compression from operating income to net income reflects material impact from non-recurring items. [Cash Quality] Cash and deposits 33.9B yen (declined 53.2% YoY), short-term debt coverage ratio 0.22x warrants monitoring for liquidity stress. Working capital items show trade receivables increased 35.1% to 199.2B yen, exceeding revenue growth rate and suggesting collection延 challenges. [Investment Efficiency] Total asset turnover 0.167, ROIC estimated at 4.2%. [Financial Health] Equity ratio 50.4% (improved from 50.2% YoY), current ratio 156.9%, quick ratio 136.8%, debt-to-equity ratio 0.98x. Short-term liabilities account for 69.2% of total liabilities, presenting refinancing considerations. Interest-bearing debt totals 225.3B yen with interest coverage ratio of 33.2x based on operating income.

Cash Flow Analysis

Cash and deposits decreased 38.5B yen YoY to 33.9B yen, representing a 53.2% contraction that significantly constrains liquidity position. The decline occurred alongside operating profit expansion, indicating substantial cash absorption in working capital and non-operating activities. Trade receivables expanded 51.7B yen to 199.2B yen, outpacing revenue growth and suggesting deterioration in collection cycles. Inventory levels remained elevated while trade payables increased 22.5B yen to 68.2B yen, reflecting extended payment terms that partially offset working capital demands. Investment securities declined 17.4B yen to 33.6B yen, consistent with the extraordinary impairment loss recognition. Short-term borrowings of 156.0B yen combined with diminished cash reserves result in a coverage ratio of 0.22x, indicating dependency on credit facility renewals. The combination of cash depletion, working capital expansion, and high short-term debt concentration creates material refinancing and liquidity considerations requiring close monitoring.

Earnings Quality

Ordinary income of 26.5B yen compared to operating income of 27.9B yen reflects a net non-operating expense of approximately 1.4B yen, primarily comprising financial costs. The extraordinary loss section recorded 24.6B yen, substantially attributed to impairment of investment securities, which depressed income before taxes to 2.0B yen from 26.5B yen at the ordinary income level. This extraordinary item represents 15.5% of quarterly revenue and constitutes a non-recurring element that should be excluded when assessing sustainable earning power. Operating income growth of 122.4% demonstrates strong operational leverage, with SG&A expenses of 40.3B yen growing more slowly than gross profit expansion. However, the quality of earnings faces headwinds from working capital dynamics, as trade receivables growth of 35.1% significantly exceeds revenue growth of 22.3%, indicating potential cash realization delays. The sharp contraction in cash despite operating income doubling suggests that accrual-based profits are not translating to proportional cash generation, warranting attention to Days Sales Outstanding and inventory turnover metrics.

Risk Factors

1. Liquidity and Refinancing Risk: Cash-to-short-term debt ratio of 0.22x combined with 156.0B yen in short-term borrowings creates material refinancing dependency. Cash reserves decreased 53.2% YoY while short-term liabilities comprise 69.2% of total debt, requiring successful credit facility renewals and working capital optimization to maintain financial flexibility.

2. Working Capital Efficiency Deterioration: Trade receivables increased 35.1% versus revenue growth of 22.3%, indicating collection cycle延. Combined with elevated inventory levels, this expansion absorbs cash and pressures operating cash flow generation despite operating profit improvement.

3. Investment Securities Valuation Risk: Recognition of 24.6B yen impairment loss in Q1 demonstrates exposure to market value fluctuations in the investment portfolio. Remaining investment securities of 33.6B yen (down 34.1% from prior year) may face additional valuation pressure depending on market conditions and portfolio composition.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis)

The company demonstrates a mixed competitive position within the pharmaceutical industry. Operating margin of 17.5% represents strong operational efficiency, supported by 122.4% year-over-year growth in operating income that reflects successful cost management and revenue scale benefits. Revenue growth of 22.3% substantially exceeds typical pharmaceutical industry organic growth rates, indicating market share gains or product cycle strength. However, net profit margin of 2.0% falls significantly below historical company performance of 7.6% and typical pharmaceutical industry profitability due to the extraordinary impairment charge. ROE of 0.7% on a quarterly basis is substantially depressed by the non-recurring loss and represents a considerable distance from pharmaceutical industry median ROE levels typically in the mid-to-high single digits. The equity ratio of 50.4% aligns with conservative pharmaceutical industry capital structures, though liquidity metrics warrant attention relative to industry peers who typically maintain higher cash-to-short-term-debt ratios. The company's asset turnover of 0.167 reflects the asset-intensive nature of pharmaceutical operations, consistent with industry characteristics of high working capital and fixed asset requirements.

※ Industry: Pharmaceutical Manufacturing, Comparison: Historical periods and general industry characteristics, Source: Proprietary analysis

Key Takeaways from Earnings

1. Operational Performance Improvement Masked by Non-Recurring Items: The quarter demonstrates substantial operational progress with operating income more than doubling year-over-year and operating margin expanding to 17.5%. This improvement in core business profitability indicates successful execution of business strategies, though the sustainability of this margin level requires monitoring across subsequent quarters to distinguish cyclical from structural improvements.

2. Critical Focus Required on Cash Conversion and Liquidity Management: Despite operating income strength, cash reserves contracted 53.2% while working capital expanded, creating a significant gap between accrual profits and cash generation. The cash-to-short-term-debt ratio of 0.22x and short-term liability concentration of 69.2% necessitate immediate attention to Days Sales Outstanding reduction, inventory optimization, and refinancing arrangements to ensure financial flexibility.

3. Dividend Sustainability Requires Scrutiny: The indicated annual dividend of 45.5 yen per share against Q1 EPS of 13.28 yen produces an exceptionally elevated implied payout ratio. Dividend sustainability depends on achievement of full-year net income guidance of 22.4B yen and successful cash flow generation, requiring investors to monitor quarterly profit trajectory and free cash flow development closely.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q1 operating performance was strong, but reported net income was severely reduced by a large non-recurring investment-security valuation loss. Revenue increased 22.3% year on year to ¥15.90bn. Operating income more than doubled, rising 122.4% to ¥2.79bn. Ordinary income rose 92.8% to ¥2.65bn, confirming that the core earnings improvement extended below operating profit. The operating margin expanded to 17.5% from 9.6% in the prior-year quarter, a material 790bp improvement and above the 15% excellent-profitability benchmark. Gross margin improved to 42.9% from 40.8%, an expansion of approximately 210bp. Gross profit increased 28.5% to ¥6.82bn, outpacing revenue growth. SG&A expense declined marginally to ¥4.03bn despite the 22.3% increase in revenue, demonstrating substantial positive operating leverage. However, a ¥2.46bn extraordinary loss on valuation of investment securities reduced profit before tax to ¥0.20bn from ¥1.37bn. Consequently, net income fell 67.2% year on year to ¥0.32bn and net margin fell to 2.0% from 7.6%. The negative ¥0.13bn tax expense produced an unusual effective tax rate of negative 65.3%, reflecting the very low pre-tax profit after the extraordinary charge rather than a normalized tax profile. Comprehensive income was ¥1.65bn, materially above net income, supported by ¥1.33bn of other comprehensive income, including foreign-currency translation and securities valuation movements. Q1 revenue represents 26.8% of the full-year forecast, broadly in line with the 25% seasonal reference point. Q1 operating income represents 45.5% of full-year guidance and ordinary income represents 45.1%, both substantially ahead of the 25% reference point, although this pace should not be extrapolated mechanically given likely quarterly seasonality. Q1 net income represents only 14.5% of the full-year forecast because of the exceptional securities valuation loss. The principal issue for the remainder of FY2026 is whether the exceptional loss remains isolated while the elevated gross margin and SG&A leverage can be maintained. Balance-sheet liquidity is adequate on current and quick ratios, but low cash relative to short-term borrowings and a long working-capital cycle warrant close monitoring.

Profitability Analysis

The reported annualized DuPont ROE is 2.7%, decomposed into a 2.0% net profit margin, 0.669x annualized asset turnover, and 1.98x financial leverage. The weakest DuPont component is the net margin, which was distorted by the ¥2.46bn extraordinary loss on investment-security valuation. Financial leverage is moderate rather than excessive, with D/E of 0.98x and debt/capital of 32.0%; leverage is therefore not the main cause of the low reported ROE. The largest operational improvement was margin expansion: gross margin increased by roughly 210bp and operating margin by roughly 790bp year on year. Revenue growth of 22.3% combined with a 0.5% reduction in SG&A created strong operating leverage, lifting operating income by 122.4%. Core profitability is also supported by ordinary income growth of 92.8%, although ordinary income growth lagged operating-income growth because net non-operating expense increased. The reported five-factor interest burden of 0.070 is not indicative of ¥2.59bn of interest expense: it is mechanically depressed because profit before tax includes the ¥2.46bn extraordinary investment-security valuation loss. Actual interest expense was ¥0.84bn and interest coverage was 33.17x, indicating that interest servicing is presently well covered by EBIT. The negative effective tax rate is similarly non-normal because the exceptional charge reduced pre-tax income to ¥0.20bn. The sustainability of the Q1 operating margin depends on continued gross-margin resilience and discipline over SG&A, while reported net-margin recovery depends principally on the absence of further securities-related valuation losses.

Growth Assessment

Top-line growth was robust at 22.3%, with revenue reaching ¥15.90bn. The gross-profit increase of 28.5% exceeded revenue growth, indicating improved unit economics or product mix during the quarter. Operating profit growth of 122.4% substantially exceeded sales growth, reflecting both gross-margin expansion and fixed-cost leverage. Full-year guidance calls for revenue of ¥59.25bn, up 14.7%, and operating income of ¥6.12bn, up 22.6%. The Q1 sales progress rate of 26.8% is close to the standard 25% pace. Operating-income progress of 45.5% is 20.5 percentage points above the standard pace, and ordinary-income progress of 45.1% is 20.1 percentage points above it. This early profit outperformance suggests either favorable Q1 mix, timing of sales and expenses, or conservative full-year assumptions. Full-year operating-margin guidance is 10.3%, well below Q1's 17.5%, implying management expects margin normalization later in the year. The full-year ordinary-income forecast is ¥5.88bn, while the net-income forecast is ¥2.24bn; the wide gap indicates that non-operating, extraordinary, and tax effects remain important to the earnings bridge. Intangible assets account for 14.7% of total assets, below the 20% concentration benchmark, providing a relatively balanced asset mix for a pharmaceutical manufacturer. The exceptional Q1 loss on investment securities, rather than deterioration in the operating business, is the principal constraint on near-term reported-profit growth.

Financial Health

Liquidity ratios are healthy on their face: the current ratio is 156.9% and the quick ratio is 136.8%, both above conventional minimum thresholds. Working capital totals ¥18.38bn. Total equity increased to ¥47.95bn from ¥46.91bn a year earlier, and the equity ratio was 50.4%, supporting balance-sheet resilience. Total interest-bearing debt was ¥22.53bn, equivalent to D/E of 0.98x and debt/capital of 32.0%; neither metric breaches the stated high-leverage warning threshold. The principal funding concern is maturity concentration: ¥15.60bn of short-term loans represent 69.2% of interest-bearing debt. Cash and deposits were only ¥3.39bn, equal to 0.22x short-term debt, which is below the 0.5x liquidity-stress threshold. Accordingly, the company relies on operating cash generation, receivables collection, inventory monetization, and refinancing capacity to manage short-term debt maturities. Cash declined 53.2% year on year, from ¥7.25bn to ¥3.39bn. Trade receivables increased 35.1% to ¥19.92bn and represented 20.9% of total assets. Trade payables increased 49.3% to ¥6.82bn, partly offsetting the funding absorbed by receivables. Investment securities declined ¥1.74bn, or 34.1%, to ¥3.36bn; the Q1 valuation loss demonstrates that this asset category can create earnings volatility. Lease obligations total ¥4.56bn across current and non-current liabilities and should be considered alongside borrowings when assessing fixed financing commitments. Net defined-benefit liability was ¥2.26bn, representing an additional long-dated obligation. The refinancing-risk alert is material because short-term debt is high relative to cash, even though overall leverage and interest coverage remain manageable.

Notable B/S Changes

Cash and deposits: -¥3.85bn (-53.2%) to ¥3.39bn - materially reduces immediate liquidity against ¥15.60bn of short-term loans. Trade receivables: +¥5.17bn (+35.1%) to ¥19.92bn - supports revenue growth but contributes to the elevated 114-day collection period and working-capital funding needs. Trade payables: +¥2.25bn (+49.3%) to ¥6.82bn - provides partial supplier-financing support against higher receivables and production-related balances. Investment securities: -¥1.74bn (-34.1%) to ¥3.36bn - the Q1 ¥2.46bn valuation loss highlights earnings sensitivity to this portfolio. Work in process: +¥0.91bn (+28.0%) to ¥4.14bn - increases capital tied up in the manufacturing cycle and should be monitored alongside inventory days. Accumulated other comprehensive income: +¥1.33bn (+48.0%) to ¥4.09bn - reflects material valuation and foreign-currency translation movements within equity.

Cash Flow Quality

Working-capital indicators point to potentially heavy cash absorption. The reported receivable collection period of 114 days exceeds the 60-day alert threshold, consistent with the sizeable ¥19.92bn receivable balance. The reported inventory indicators are elevated: inventory days of 225 days and finished-goods inventory days of 65 days both exceed their respective alert thresholds. Raw materials of ¥11.78bn and work in process of ¥4.14bn add to the operating capital tied up across the production cycle. The reported cash conversion cycle of 271 days is substantially above the 120-day warning benchmark. These conditions increase reliance on short-term funding and heighten the importance of collection discipline, demand forecasting, production planning, and inventory-obsolescence control. The 49.3% increase in trade payables provides some supplier-financing offset, but it does not eliminate the liquidity impact of receivable and inventory balances. The ¥2.46bn investment-security valuation loss is non-cash at recognition but materially lowers reported earnings, making cash-based earnings assessment especially important.

Dividend Sustainability

The full-year dividend forecast is ¥47.00 per share, compared with forecast EPS of ¥91.54. The implied dividend payout ratio is approximately 51.3%, within the stated sub-60% sustainability benchmark. The forecast dividend is therefore supported by expected annual earnings if management achieves its ¥2.24bn net-income target. Q1 EPS was ¥13.28, depressed by the exceptional securities valuation loss, and should not be used alone to assess the full-year dividend capacity. Retained earnings of ¥35.92bn provide a meaningful equity reserve relative to the forecast cash dividend commitment. Dividend resilience nevertheless depends on the company converting operating profit into cash while managing the elevated receivable and inventory cycle and refinancing short-term loans.

Risk Assessment

Business risks include Working-capital execution risk is high: reported DSO of 114 days, inventory days of 225 days, finished-goods days of 65 days, and a 271-day cash conversion cycle indicate significant capital lock-up across collection and production., Pharmaceutical manufacturing and product-demand risk remains relevant because high raw-material and work-in-process balances can expose the company to demand-forecast errors, expiry or obsolescence, and inventory write-downs., The Q1 operating margin of 17.5% is materially above the 10.3% implied by full-year guidance; later-quarter margin normalization would reduce the apparent strength of the Q1 run rate., Investment-security valuation risk is evidenced by the ¥2.46bn extraordinary loss, which transformed strong operating and ordinary-income growth into a 67.2% decline in net income..

Financial risks include Refinancing risk is elevated because ¥15.60bn of short-term loans comprise 69.2% of interest-bearing debt, above the 40% warning threshold., Liquidity stress is present at the cash level: cash of ¥3.39bn covers only 0.22x of short-term debt, below the 0.5x alert level., The high-interest-burden alert requires careful interpretation: the 0.070 reported interest burden is driven primarily by the extraordinary valuation loss reducing pre-tax profit, while actual interest coverage remains strong at 33.17x., Foreign-currency translation and securities valuation movements contributed to other comprehensive income, indicating that equity can fluctuate with market and currency conditions..

Key concerns include Priority one is the combination of low cash, concentrated short-term debt, and a long cash conversion cycle., Priority two is recurrence risk from investment-security valuation losses and their potential to disrupt reported earnings and dividend coverage., Priority three is whether Q1 gross-margin and SG&A leverage gains can be sustained as the fiscal year progresses., The negative effective tax rate is not representative of normalized profitability because the exceptional loss left very low pre-tax income..

Investment Implications

Key takeaways include Core Q1 earnings were strong: revenue rose 22.3%, operating income rose 122.4%, and operating margin expanded 790bp to 17.5%., Reported net income of ¥0.32bn understated operating performance because of a ¥2.46bn extraordinary loss on investment-security valuation., Operating-income and ordinary-income progress rates of 45.5% and 45.1%, respectively, are well ahead of the 25% Q1 reference pace, whereas net-income progress is only 14.5%., The balance sheet has adequate ratio-based liquidity and moderate aggregate leverage, but short-term debt concentration and low cash coverage create a meaningful funding-management issue., The forecast dividend payout ratio of about 51.3% appears earnings-supported, subject to working-capital cash conversion and the absence of further exceptional losses..

Metrics to watch include Operating margin relative to the 17.5% Q1 result and 10.3% full-year guided level, Receivable days, inventory days, cash conversion cycle, and trade-payable development, Cash and deposits relative to ¥15.60bn of short-term loans, Refinancing of short-term borrowings and changes in total interest-bearing debt, Additional investment-security valuation gains or losses, Progress toward full-year revenue guidance of ¥59.25bn, operating-income guidance of ¥6.12bn, and net-income guidance of ¥2.24bn.

Regarding relative positioning, The company shows above-benchmark Q1 operating profitability and healthy current and quick ratios, while its reported ROE and net margin are temporarily weak due to an exceptional securities valuation loss. Relative to the stated balance-sheet benchmarks, aggregate leverage is acceptable, but the short-term funding profile and extended operating cash cycle are less favorable and deserve greater attention than the headline current ratio.